It has been a volatile year for BioNTech (BNTX +2.93%), an mRNA-based vaccine specialist. The company's financial results ...

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.

Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...

Personalized mRNA cancer vaccines are showing early success in clinical trials, fueling optimism in the fight against cancer.

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P ...

Doctors discovered that Johnson had stage 2B triple-negative breast cancer, a rare and aggressive form. They treated her with ...

Personalized cancer vaccines are attracting growing attention as advances in mRNA technology open up new possibilities across oncology.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient ...